Table 1.
Prevalence, incidence, and persistence or redetection of genital infection with carcinogenic HPV genotypes in 2185 female students, of whom 821 (38%) returned follow-up samples after a median of 16 months
| Carcinogenic HPV genotype | Prevalence (infected at baseline) | Incidence (new infection at follow-up) | Persistence or redetection (same HPV type at follow-up)* | |||||
|---|---|---|---|---|---|---|---|---|
| No (%) infected of 2185 women tested | % of 404 women infected with each genotype | No (%) of women tested† | % of 145 women infected with each genotype | No (%) of women with specific HPV type at baseline | % of 20 women infected with each genotype | |||
| Any | 404 (18.5) | 100 | 145/821 (17.7) | 100 | 20/143 (14)‡ | 100 | ||
| 16 | 118 (5.4) | 29.2 | 45/775 (5.8) | 31.0 | 11/46 (24) | 55 | ||
| 18 | 50 (2.3) | 12.4 | 12/801 (1.5) | 8.3 | 2/20 (10) | 10 | ||
| 31 | 40 (1.8) | 9.9 | 16/810 (2.0) | 11.0 | 2/11 (18) | 10 | ||
| 33 | 21 (1.0) | 5.2 | 3/813 (0.4) | 2.1 | 0/8 | 0 | ||
| 35 | 20 (0.9) | 5.0 | 5/816 (0.6) | 3.4 | 0/5 | 0 | ||
| 39 | 30 (1.4) | 7.4 | 7/809 (0.9) | 4.8 | 0/12 | 0 | ||
| 45 | 29 (1.3) | 7.2 | 9/815 (1.1) | 6.2 | 3/6 (50) | 15 | ||
| 51 | 97 (4.4) | 24.0 | 29/787 (3.7) | 20.0 | 0/34 | 0 | ||
| 52 | 52 (2.4) | 12.9 | 22/805 (2.7) | 15.2 | 1/16 (6) | 5 | ||
| 56 | 28 (1.3) | 6.9 | 11/811 (1.4) | 7.6 | 0/10 | 0 | ||
| 58 | 41 (1.9) | 10.1 | 12/812 (1.5) | 8.3 | 0/9 | 0 | ||
| 59 | 53 (2.4) | 13.1 | 23/805 (2.9) | 15.9 | 2/16 (13) | 10 | ||
| 68 | 16 (0.7) | 4.0 | 5/817 (0.6) | 3.4 | 1/4 (25) | 5 | ||
| 16,18, or both | 159 (7.3) | 39.4 | 50/758 (6.6) | 34.5 | 13/63 (21)‡ | 65 | ||
| ≥2 genotypes | 144 (6.6) | 35.6 | 43/821 (5.2) | 29.7 | 4/40 (10)‡ | 20 | ||
| Non-vaccine genotypes§ | 327 (15.0) | 80.9 | 110/821 (13.4) | 75.9 | 9/104 (9)‡ | 45 | ||
Percentages for individual genotypes sum to >100% because women could be infected with >1 genotype.
*Detection of same carcinogenic HPV genotype in baseline and follow-up samples.
†Denominators exclude women with the same HPV genotype at baseline.
‡Infected with any of the same genotypes at follow-up.
§Defined as not HPV types 16 or 18.